標題
返回
確定
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
bispecific antibody
#
bispecific antibody
About 5 search results
Sort by Date
Business
PR Newswire
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
SHANGHAI
PR Newswire
2026-06-24 08:00
6MW5311
Mabwell
LILRB4/CD3
Business
PR Newswire
Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 -
PR Newswire
2026-06-15 19:00
BBT002
Bambusa Therapeutics
bispecific antibody
Business
PR Newswire
Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI
PR Newswire
2026-06-10 12:06
Harbour BioMed
HBM7004
NMPA
Business
PR Newswire
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China
PR Newswire
2026-06-04 18:58
Kexing Biopharm
GB10
ophthalmic drug
Business
PR Newswire
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
CHICAGO
PR Newswire
2026-05-31 21:00
ivonescimab
HARMONi-6
sq-NSCLC